Trial Profile
Safety and Efficacy Evaluation of IM19 Chimeric Antigen Receptor-modified T Cells (IM19CAR-T) In CD19+ B Cell Malignancies
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs IM19 chimeric antigen receptor T cell therapy Beijing Immunochina Medical Science and Technology (Primary) ; Cyclophosphamide; Fludarabine
- Indications Chronic lymphocytic leukaemia; Haematological malignancies; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Beijing Immunochina Medical Science and Technology
- 20 Nov 2017 New trial record